August 2023 Newsletter Prepared by Van Scoyoc Associates

KFF Tracking Poll: Substance Use Crisis and Accessing Treatment

According to a new KFF poll, nearly a third of U.S. adults said they or someone in their family has been addicted to opioids. Read more here.

Vaping CBD Popular Among U.S. Teens

A study in *JAMA Network Open* found a high prevalence of vaping cannabidiol, or CBD, among adolescent e-cigarette users in the U.S. Read more here.

Marijuana and Hallucinogen Use Reached Historic Highs

According to NIDA's Monitoring the Future study, past-year use of marijuana and hallucinogens by adults 35 to 50 years old continued a long-term upward trajectory to reach all-time highs in 2022. Read more here.

NIDA Blog Post on Implementing Substance Use Prevention in Primary Care

Read Dr. Nora Volkow's blog post on innovative projects answering NIDA's challenge to implement substance use prevention in primary care. Read more <u>here</u>.

Upcoming NIDA Webinar

In February 2023, NIDA announced the <u>"Substance Use Prevention Services in Primary Care" Challenge</u>. A September 19 webinar will provide an overview of the three winning primary care models and discuss opportunities for implementation and sustainability of prevention services in primary care. Register and read more <u>here</u>.

Cannabis Use Disorder is More Prevalent Among Recreational Users

According to a new study, cannabis use disorder is more common in Washington state, where marijuana sales have been legal since 2014, compared to states without commercial adult-use markets. Read more here.

HHS Recommends DEA Move Marijuana to Schedule III

The Department of Health and Human Services is calling on DEA to reclassify marijuana as a Schedule III drug under the Controlled Substances Act. Read more here.

CDC: Deaths from Counterfeit Pills Rising

Fatal overdoses from counterfeit pharmaceuticals, particularly pills found to contain fentanyls, more than doubled in recent years, the CDC reported. Read more here.